Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.

SELARL PHARMACIE PRINCIPALE DOSSET : revenue, balance sheet and financial ratios

SELARL PHARMACIE PRINCIPALE DOSSET is a French company founded 14 years ago, specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé. Based in BAPAUME (62450), this company of category PME shows in 2025 a net income positive of 125 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-02

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - SELARL PHARMACIE PRINCIPALE DOSSET (SIREN 535269054)
Indicator 2025 2024 2023 2019 2018 2017 2016 2015
Revenue N/C N/C N/C N/C N/C N/C N/C N/C
Net income 124 824 € 135 204 € 141 543 € 168 444 € 194 661 € 45 560 € -47 152 € 54 666 €
EBITDA N/C N/C N/C N/C N/C N/C N/C N/C
Net margin N/C N/C N/C N/C N/C N/C N/C N/C

Revenue and income statement

In 2025, SELARL PHARMACIE PRINCIPALE DOSSET generates positive net income of 125 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2015-2025: 55 k€ -> 125 k€.

Net income (2025) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

124 824 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 88%. Debt level is high: negotiating margin with banks is reduced. Financial autonomy (= Equity / Total assets x 100) reaches 45%. This high autonomy means the company finances most of its assets through equity, a sign of strength.

Debt ratio (2025) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

87.778%

Financial autonomy (2025) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

45.101%

Asset age ratio (2025) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

87.9%

Solvency indicators evolution
SELARL PHARMACIE PRINCIPALE DOSSET

Sector positioning

Debt ratio
87.78 2025
2023
2024
2025
Q1: 13.7
Med: 49.79
Q3: 129.09
Average +10 pts over 3 years

In 2025, the debt ratio of SELARL PHARMACIE PRINCIPA... (87.78) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
45.1% 2025
2023
2024
2025
Q1: 33.42%
Med: 53.72%
Q3: 72.08%
Average -8 pts over 3 years

In 2025, the financial autonomy of SELARL PHARMACIE PRINCIPA... (45.1%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 127.76. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2025) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

127.757

Liquidity indicators evolution
SELARL PHARMACIE PRINCIPALE DOSSET

Sector positioning

Liquidity ratio
127.76 2025
2023
2024
2025
Q1: 131.03
Med: 182.25
Q3: 258.64
Watch

In 2025, the liquidity ratio of SELARL PHARMACIE PRINCIPA... (127.76) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.

Positioning of SELARL PHARMACIE PRINCIPALE DOSSET in its sector

Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé

Valuation estimate

Based on 277 transactions of similar company sales in 2025, the value of SELARL PHARMACIE PRINCIPALE DOSSET is estimated at 1 982 844 € (range 1 345 567€ - 3 111 355€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2025
277 transactions
1345k€ 1982k€ 3111k€
1 982 844 € Range: 1 345 567€ - 3 111 355€
NAF 5 année 2025

Valuation method used

Net Income Multiple
124 824 € × 15.9x = 1 982 844 €
Range: 1 345 567€ - 3 111 355€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)

Compare SELARL PHARMACIE PRINCIPALE DOSSET with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de détail de produits pharmaceutiques en magasin spécialisé

Frequently asked questions about SELARL PHARMACIE PRINCIPALE DOSSET

What is the revenue of SELARL PHARMACIE PRINCIPALE DOSSET ?

The revenue of SELARL PHARMACIE PRINCIPALE DOSSET is not publicly disclosed (confidential accounts filed with INPI).

Is SELARL PHARMACIE PRINCIPALE DOSSET profitable?

Yes, SELARL PHARMACIE PRINCIPALE DOSSET generated a net profit of 125 k€ in 2025.

Where is the headquarters of SELARL PHARMACIE PRINCIPALE DOSSET ?

The headquarters of SELARL PHARMACIE PRINCIPALE DOSSET is located in BAPAUME (62450), in the department Pas-de-Calais.

Where to find the tax return of SELARL PHARMACIE PRINCIPALE DOSSET ?

The tax return of SELARL PHARMACIE PRINCIPALE DOSSET is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does SELARL PHARMACIE PRINCIPALE DOSSET operate?

SELARL PHARMACIE PRINCIPALE DOSSET operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.